Immunocompatibility of a new dual modality contrast agent based on radiolabeled iron-oxide nanoparticles
Abstract Radiolabeled magnetic nanoparticles are promising candidates as dual-modality-contrast-agents (DMCA) for diagnostic applications. The immunocompatibility of a new DMCA is a prerequisite for subsequent in vivo applications. Here, a new DMCA, namely Fe3O4 nanoparticles radiolabeled with 68Ga,...
Saved in:
Main Authors: | Maria-Argyro Karageorgou, Dimosthenis Stamopoulos |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f9189ee69ced4cb9ba8b1377a0369d06 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma
by: Liang J, et al.
Published: (2017) -
A Dual-Modality MR/PA Imaging Contrast Agent Based on Ultrasmall Biopolymer Nanoparticles for Orthotopic Hepatocellular Carcinoma Imaging
by: Sun J, et al.
Published: (2019) -
Bombesin-functionalized superparamagnetic iron oxide nanoparticles for dual-modality MR/NIRFI in mouse models of breast cancer
by: Li L, et al.
Published: (2019) -
Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents
by: Estelrich J, et al.
Published: (2015) -
Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies
by: Iancu SD, et al.
Published: (2020)